Pharmacokinetics of asciminib in the presence of CYP3A or P‐gp inhibitors, CYP3A inducers, and acid‐reducing agents

• Main Authors: Matthias Hoch (Author), Felix Huth (Author), Masahiko Sato (Author), Tirtha Sengupta (Author), Michelle Quinlan (Author), Stephanie Dodd (Author), Shruti Kapoor (Author), Florence Hourcade‐Potelleret (Author)
• Format: Book
• Published: Wiley, 2022-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Asciminib is a first‐in‐class inhibitor of BCR::ABL1, specifically targeting the ABL myristoyl pocket. Asciminib is a substrate of CYP3A4 and P‐glycoprotein (P‐gp) and possesses pH‐dependent solubility in aqueous solution. This report summarizes the results of two phase I studies in healthy...